Publication | Open Access

Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data

Neck CancerOncologyMedicinePathologyImmune Checkpoint InhibitorHead And Neck CancerPharmacotherapyCancer TreatmentNeck Oncology1-Year Survival DataPharmacologyRadiation Oncology